Program Description
Graft-versus-host
disease (GVHD) remains the primary driver of non-relapse morbidity and
mortality following allogeneic hematopoietic cell transplantation (allo-HCT),
creating a persistent clinical burden and reducing long-term survivorship for
patients. While conventional prophylaxis has improved outcomes, patients still
face significant risks of chronic GVHD, prolonged immunosuppression, and
opportunistic infections. Presented in collaboration with the American Society
for Transplantation and Cellular Therapy, this program will review novel
graft-engineering strategies with faculty offering expert analysis on how these
precision platforms differ from unmanipulated peripheral blood stem cell or
bone marrow grafts. A review of clinical data comparing these
"prophylaxis-light" engineered models against current standards of
care will focus on key survival end points, the reduction of chronic GVHD
burden, and the potential for accelerated, robust immune reconstitution.
Included case-based discussions will examine approaches for oncology and
transplant pharmacists to lead multidisciplinary discussions on graft
selection, anticipate unique safety profiles, and optimize immune recovery for
better quality of life among patients with GVHD.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 29, 2026
Expiration date: April 29, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify graft-engineering strategies for graft-versus-host disease (GVHD) prophylaxis, focusing on mechanisms, efficacy, safety, and clinical impact on chronic GVHD
- Examine evidence on chronic GVHD risk, immune recovery, quality of life, and long-term immunosuppression to guide multidisciplinary care and survivorship in allogeneic transplant recipients
- Adapt operational and logistical factors for integrating emerging prophylaxis platforms, including those exploring reduced or limited GVHD prophylaxis into practical transplant workflows
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Oncology Pharmacist
Clinical Pharmacy Manager
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center
Kansas City, KS
Kevin Hall, PharmD, BCOP
Oncology Clinical Manager, Clinical Pharmacy
Specialist in Bone Marrow Transplant
Winship Cancer Institute of Emory Healthcare
Atlanta, GA
Rawan Faramand, MD
Associate Member, Blood & Marrow Transplant and Cellular Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, FL
Accreditation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.1CEU) under the ACPE universal activity number 0290-0000-26-102-H01-P. The activity is available for CE credit through April 29, 2027
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA , has the following relevant financial relationships with ineligible companies to disclose:
Consultant: Bristol Myers Squibb, Genetech, Genmab, A/S, Pfizer, Sanofi
Kevin Hall, PharmD, BCOP , has the following relevant financial relationships with ineligible companies to disclose:
Grant/Research: Sanofi
Consultant: CSL Behring, Sanofi
Rawan Faramand, MD , has the following relevant financial relationships with ineligible companies to disclose:
Grant/Research: Novartis
Consultant: Kite/Gilead, Melinta, Novartis, Sanofi
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational
purposes and do not constitute any form of professional advice or referral.
Discussions concerning drugs, dosages, and procedures may reflect the clinical
experience of the author(s) or be derived from the professional literature or
other sources and may suggest uses that are investigational in nature and not
approved by the labeling or indications. Participants are encouraged to refer
to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms